Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COASTAL study of zandelisib + rituximab versus standard immunochemotherapy in relapsed indolent non-Hodgkin lymphoma
NL-OMON51210Phase 3Completed
- Sponsor
- MEI Pharma
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zandelisib and rituximab in indolent lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by MEI Pharma. Primary endpoint: Progression-free survival. Started Jan 2022; status: completed.
02
Drugs
zandelisibrituximab
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON51210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51210.